Rice Hall James & Associates LLC Has $3.50 Million Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

Rice Hall James & Associates LLC lifted its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 59.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 989,635 shares of the company’s stock after purchasing an additional 367,970 shares during the period. Rice Hall James & Associates LLC owned 1.98% of scPharmaceuticals worth $3,503,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Rubric Capital Management LP lifted its holdings in shares of scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after purchasing an additional 1,250,000 shares during the period. Sanctuary Advisors LLC bought a new position in scPharmaceuticals during the third quarter worth $75,000. XTX Topco Ltd bought a new position in scPharmaceuticals during the third quarter worth $124,000. Suvretta Capital Management LLC bought a new position in scPharmaceuticals during the third quarter worth $9,343,000. Finally, State Street Corp raised its stake in scPharmaceuticals by 5.2% during the third quarter. State Street Corp now owns 682,135 shares of the company’s stock worth $3,111,000 after buying an additional 33,879 shares during the last quarter. Institutional investors and hedge funds own 89.52% of the company’s stock.

scPharmaceuticals Stock Down 1.1 %

SCPH opened at $3.64 on Wednesday. scPharmaceuticals Inc. has a 1-year low of $3.08 and a 1-year high of $6.54. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The company has a fifty day moving average price of $3.39 and a two-hundred day moving average price of $4.06.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on SCPH shares. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, November 14th. Craig Hallum lowered their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.